PF614 + Oxycodone Hydrochloride 40 mg + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recreational Drug Use
Conditions
Recreational Drug Use
Trial Timeline
Oct 5, 2022 → Dec 28, 2022
NCT ID
NCT05571345About PF614 + Oxycodone Hydrochloride 40 mg + Placebo
PF614 + Oxycodone Hydrochloride 40 mg + Placebo is a phase 1 stage product being developed by Ensysce Biosciences for Recreational Drug Use. The current trial status is completed. This product is registered under clinical trial identifier NCT05571345. Target conditions include Recreational Drug Use.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05571345 | Phase 1 | Completed |
Competing Products
4 competing products in Recreational Drug Use
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lasmiditan + Alprazolam + Placebo | Eli Lilly | Phase 1 | 33 |
| Lorazepam + AZD7325 + Placebo | AstraZeneca | Phase 1 | 33 |
| ACT-541468 + Suvorexant + Zolpidem + Placebo | Idorsia | Phase 1 | 28 |
| PF614 + Oxycodone | Ensysce Biosciences | Phase 1 | 25 |